Abstract
The progress in the understanding of biological events underlying multiple myeloma (MM) development and progression has allowed the design of molecularly targeted therapies (MTTs) for this disease and several new compounds are presently under investigation in the preclinical and clinical settings. The recent discovery that miRNAs, and short non coding RNAs in general, are involved in the pathogenesis of cancer has raised the issue whether a novel therapeutic approach should be provided by selective interference with miRNA network. This review will focus on the rationale of miRNA-based therapeutics, providing the most relevant information on biogenesis and technical issues in miRNA analysis. Finally, a detailed overview of the recent findings on miRNA therapeutics of MM will be discussed.
Keywords: Bone disease, microRNA, miRNA, multiple myeloma, non coding RNA, target therapy
Current Drug Targets
Title:From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Volume: 14 Issue: 10
Author(s): Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Daniele Caracciolo, Pierosandro Tagliaferri and Pierfrancesco Tassone
Affiliation:
Keywords: Bone disease, microRNA, miRNA, multiple myeloma, non coding RNA, target therapy
Abstract: The progress in the understanding of biological events underlying multiple myeloma (MM) development and progression has allowed the design of molecularly targeted therapies (MTTs) for this disease and several new compounds are presently under investigation in the preclinical and clinical settings. The recent discovery that miRNAs, and short non coding RNAs in general, are involved in the pathogenesis of cancer has raised the issue whether a novel therapeutic approach should be provided by selective interference with miRNA network. This review will focus on the rationale of miRNA-based therapeutics, providing the most relevant information on biogenesis and technical issues in miRNA analysis. Finally, a detailed overview of the recent findings on miRNA therapeutics of MM will be discussed.
Export Options
About this article
Cite this article as:
Rossi Marco, Amodio Nicola, Martino Teresa Di Maria, Caracciolo Daniele, Tagliaferri Pierosandro and Tassone Pierfrancesco, From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990186
DOI https://dx.doi.org/10.2174/13894501113149990186 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics Drug Resistance and Methylation in Myelodysplastic Syndrome
Current Pharmaceutical Biotechnology Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors
Current Pharmacogenomics Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients
Current Pharmaceutical Design Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches
Current Pharmaceutical Design A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review
Clinical Cancer Drugs Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]
Current Drug Targets Systems Biology Approaches to a Rational Drug Discovery Paradigm
Current Topics in Medicinal Chemistry Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
Current Pharmaceutical Design Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets